Summary
Background Superinfections, including invasive pulmonary aspergillosis (IPA), are well-known complications of critically ill patients with severe viral pneumonia. Aim of this study was to evaluate the incidence, risk factors and outcome of IPA in critically ill patients with severe COVID-19 pneumonia.
Methods We prospectively screened 32 critically ill patients with severe COVID-19 pneumonia for a time period of 28 days using a standardized study protocol for oberservation of developement of COVID-19 associated invasive pulmonary aspergillosis (CAPA). We collected laboratory, microbiological, virological and clinical parameters at defined timepoints in combination with galactomannan-antigen-detection from bronchial aspirates. We used logistic regression analyses to assess if COVID-19 was independently associated with IPA and compared it with matched controls.
Findings CAPA was diagnosed at a median of 4 days after ICU admission in 11/32 (34%) of critically ill patients with severe COVID-19 pneumonia as compared to 8% in the control cohort.
In the COVID-19 cohort, mean age, APACHE II score and ICU mortality were higher in patients with CAPA than in patients without CAPA (36% versus 9.5%; p<0.001). ICU stay (21 versus 17 days; p=0.340) and days of mechanical ventilation (20 versus 15 days; p=0.570) were not different between both groups. In regression analysis COVID-19 and APACHE II score were independently associated with IPA.
Interpretation CAPA is highly prevalent and associated with a high mortality rate. COVID-19 is independently associated with invasive pulmonary aspergillosis. A standardized screening and diagnostic approach as presented in our study can help to identify affected patients at an early stage.
Funding None
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional review board, Klinikum rechts der Isar, TU Muenchen (Ref. 149/20S). Written informed consent was obtained by the patient or their legal representatives
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Authors’ email addresses
Tobias Lahmer: TobiasLahmer{at}me.com
Silja Kriescher: Silja.Kriescher{at}tum.de
Alexander Herner: Alexander.Herner{at}tum.de
Kathrin Rothe: Kathrin.Rothe{at}tum.de
Christoph D. Spinner: Christoph.spinner{at}tum.de
Jochen Schneider: Jochen.Schneider{at}tum.de
Ulrich Mayer: Ulrich.Mayer{at}tum.de
Michael Neuenhahn: Michael.Neuenhahn{at}tum.de
Dieter Hoffmann: Dieter.Hofmann{at}tum.de
Fabian Geisler: fabian.geisler{at}tum.de
Markus Heim: Markus.Heim{at}tum.de
Gerhard Schneider: gerhard.schneider{at}tum.de
Roland M. Schmid: roland.schmid{at}tum.de
Wolfgang Huber: wolfgang.huber{at}tum.de
Sebastian Rasch: Sebastian.Rasch{at}tum.de
Data Availability
The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. Due to ethical and legal restrictions, confidential data are available upon request. To receive anonymized data readers are welcome to contact the corresponding author.
